AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7835811
Drug: Observation (adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (adjuvant treatment)
Trial: 3680564
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) dextromethorphan (DM) suspension 60 mg bid
Trial: 3680564
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) DM solution 30 mg qid
Trial: 25910532
Drug: remifentanil (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil (0.4 μg/kg per minute) and saline solution
Trial: 22981952
Drug: Placebo, n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, n = 40, orally, in 5 drops, 1 time daily, for 21 days
Trial: 20350523
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg at 12 h pre-PCI and 40 mg at 2 h pre-PCI, followed by atorvastatin 40 mg/day for 30 days post-PCI
Trial: 20350523
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care including atorvastatin 40 mg/day for 30 days post-PCI
Trial: 12860331
Drug: Ureaplasma urealyticum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ureaplasma urealyticum positive cultures (>10(5) cfu/ml) in endometritis patients (39% of 67 patients)
Trial: 8181026
Drug: Nonglycosidic inotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonglycosidic inotropic drugs (vesnarinone and ibopamine)
Trial: 8181026
Drug: Adrenergic agents
RxNorm normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic agents and phosphodiesterase inhibitors
Trial: 28666080
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) at a standard dose (200 mg every 2 weeks plus optimized methotrexate)
Trial: 23328304
Drug: 4-galactosylxylose (gaxilose)
RxNorm normalized name: Gaxilose
DrugBank: Gaxilose (DB12767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-galactosylxylose (gaxilose) at doses of 0.45 g for urine tests and 2.7 g for blood tests
Trial: 20549321
Drug: Thymosin alpha
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha 1 (TA1) 3.2 mg twice per day for 7 days
Trial: 20549321
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy for SAP
Trial: 17448266
Drug: Estrogen, selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen, selective estrogen receptor modulators (SERMs), and bisphosphonates (when given in combination with calcium and vitamin D)
Trial: 10776742
Drug: Regular-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular-dose aprotinin
Trial: 11795347
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (HRT)
Trial: 9459084
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg i.m. leuprolide acetate (LA) every 4 weeks for 24 weeks
Trial: 8043891
Drug: Nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (30 mg/day)
Trial: 31156221
Drug: neuroleptic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neuroleptic therapy in combination with intravenous infusions of remaxol (400.0 ml)
Trial: 27956428
Drug: MEDI8897 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI8897 (300 mg i.m.)
Trial: 27956428
Drug: MEDI8897 (i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI8897 (i.m. dosing)
Trial: 26115690
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser plus routine physical therapy program (RPTP)
Trial: 23557930
Drug: GSK1322322 (500-1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 (500-1500 mg)
Trial: 23557930
Drug: GSK1322322 (1000-1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 (1000-1500 mg)
Trial: 21747084
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) and pemetrexed (500 mg/m(2)) every 21 days for four cycles and thoracic radiation therapy (TRT) (70 Gy) with cetuximab administered concurrent only with TRT
Trial: 15248052
Drug: New Carisolv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Carisolv gel (higher concentration of sodium hypochlorite)
Trial: 8235809
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy with advice for daily life by a physiotherapist
Trial: 8235809
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound therapy by a physiotherapist
Trial: 3321756
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Ibuprofen q.i.d. as pellets
Trial: 3321756
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg Ibuprofen b.i.d. as dragees
Trial: 31940011
Drug: Family-Focused Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Focused Therapy (FFT) - 12 sessions in 4 months of psychoeducation, communication training, and problem-solving skills training
Trial: 26797192
Drug: Low-level light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level light therapy using the Color DNA-WSF device
Trial: 26797192
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with a dummy device
Trial: 18583261
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg/day)
Trial: 17602039
Drug: Rocuronium 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.45 mg.kg(‐1) iv (1.5 x ED(95))
Trial: 17602039
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg.kg(‐1) iv (2.0 x ED(95))
Trial: 27265451
Drug: PRP-CRM197 vaccine
RxNorm normalized name: Globo H-CRM197 vaccine
DrugBank: OBI-833 (DB19270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-CRM197 vaccine
Trial: 8337029
Drug: PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T vaccine
Trial: 27265451
Drug: PRP-CRM197 vaccine
RxNorm normalized name: Globo H-CRM197 vaccine
DrugBank: OBI-833 (DB19270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-CRM197 vaccine with DTaP
Trial: 27265451
Drug: PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-T vaccine with DTaP
Trial: 19841897
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (5-15 microg/min)
Trial: 17478939
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg intravenously twice daily
Trial: 17478939
Drug: Ranitidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine treatment group
Trial: 16983112
Drug: Exatecan plus
RxNorm normalized name: Exatecan
DrugBank: Exatecan (DB12185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exatecan plus gemcitabine (exatecan 2.0 mg/m2 and gemcitabine 1,000 mg/m2 on days 1 and 8, every 3 weeks)
Trial: 8568135
Drug: Local nasal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local nasal immunotherapy with allergen in powder form
Trial: 6889140
Drug: Elixophyllin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elixophyllin 400 mg capsule
Trial: 6889140
Drug: Elixophyllin 373
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elixophyllin 373 mg elixir
Trial: 6889140
Drug: Theolair 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theolair 375 mg tablet
Trial: 30971235
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CYC) added to high-dose corticosteroids
Trial: 30971235
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to high-dose corticosteroids
Trial: 26160253
Drug: Aggressive early
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aggressive early feeding guidelines (enteral and parenteral nutrition)
Trial: 11131781
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (400 microg)
Trial: 17579200
Drug: VA2914 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VA2914 (5 mg/d)
Trial: 10575335
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia without volatile anesthetics
Trial: 7568654
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy plus consultation
Trial: 2291838
Drug: Metformin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1.0 g/day
Trial: 27930939
Drug: Guided Parent-delivered
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT) for 2.6 hours
Trial: 27930939
Drug: Guided Parent-delivered
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT) for 5.3 hours
Trial: 27930939
Drug: Guided Parent-delivered
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT)
Trial: 21055588
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups pooled
Trial: 23964994
Drug: benfotiamine 900
RxNorm normalized name: BENFOTIAMINE
DrugBank: Benfotiamine (DB11748)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benfotiamine 900 mg/day for 6 weeks
Trial: 18310262
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori test and treat (H pylori 13C urea breath test plus one week of eradication treatment if positive)
Trial: 11039005
Drug: Auricular-plaster therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular-plaster therapy plus acupuncture at Zusanli (ST 36)
Trial: 8721275
Drug: Total percentages
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total percentages of metabolites recovered in urine after i.v. administration
Trial: 8721275
Drug: Total percentages
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total percentages of metabolites recovered in urine after i.c. administration without a tourniquet
Trial: 8721275
Drug: Total percentages
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total percentages of metabolites recovered in urine after i.c. administration with a tourniquet
Trial: 1443353
Drug: Cefotaxime (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1-g single dose 30 minutes before surgery)
Trial: 1443353
Drug: Cefoxitin (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (1-g dose 30 minutes before surgery and 1 g every 6 hours for 24 hours, total dose 4 g)
Trial: 1443353
Drug: Cefazolin (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1-g dose 30 minutes before surgery, followed by 1 g every 8 hours for 48 hours, total dose 6 g)
Trial: 3904673
Drug: Polyester antimicrobial
RxNorm normalized name: polyester-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyester antimicrobial incise drape (loban 2 Antimicrobial Film) with one-minute skin preparation using 70% alcohol or 2% iodine in 90% alcohol
Trial: 3904673
Drug: Standard ten-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ten-minute skin preparation with Betadine
Trial: 29244026
Drug: Pimodivir 1,200/600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimodivir 1,200/600 mg
Trial: 22486142
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ketamine
Trial: 20360429
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic drug (ND)
Trial: 11302304
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg sodium hyaluronate
Trial: 9288374
Drug: Oxygen via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen via a facemask at 4 l/min
Trial: 8323999
Drug: Phosphatidylserine (BC-PS)
RxNorm normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylserine (BC-PS) 300 mg/day for 6 months
Trial: 3521254
Drug: Formulas I
RxNorm normalized name: Jarrow Formulas Inositol 750mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulas I and V providing 13 g protein and 350 kcal per day
Trial: 30803326
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (room-temperature bag)
Trial: 17617270
Drug: TMC125 (etravirine)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TMC125 (etravirine) 200 mg twice daily
Trial: 11756100
Drug: Gadobutrol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadobutrol (1 mol/L) injected IV at doses of 0.1 or 0.3 mmol/kg
Trial: 11756100
Drug: Gadobutrol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadobutrol (1 mol/L) injected IV
Trial: 2660319
Drug: 4 capsules
RxNorm normalized name: Jynarque 60 MG / 30 MG Carton Pack, 4 Blister Cards, 14 Capsules Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules with 1 g concentrated fish oil preparation daily for 4 weeks (equivalent to 3.4 grams of EPA and DHA).
Trial: 2660319
Drug: 4 capsules
RxNorm normalized name: Jynarque 60 MG / 30 MG Carton Pack, 4 Blister Cards, 14 Capsules Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules with 1 g concentrated fish oil preparation daily for 4 weeks (equivalent to 3.4 grams of EPA and DHA) in patients receiving OAC.
Trial: 31136070
Drug: Zero dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zero dose of antibiotic prophylaxis (ABP)
Trial: 31136070
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ABP (30 min before surgery)
Trial: 31136070
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of ABP
Trial: 28553988
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg intravenous acetaminophen
Trial: 28553988
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg intravenous acetaminophen
Trial: 23648697
Drug: Low-gluten diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-gluten diet (2 g gluten/d and 14 g whey protein/d)
Trial: 23648697
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (16 g whey protein/d)
Trial: 23648697
Drug: Gluten diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten diet (16 g/d)
Trial: 23648697
Drug: Whey diet
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey diet (16 g/d)
Trial: 8443029
Drug: Atenolol up
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol up to 100 mg
Trial: 8443029
Drug: Atenolol up
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol up to 100 mg in combination with hydrochlorothiazide 25 mg
Trial: 3097384
Drug: Glibenclamide +
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glibenclamide + Insulin infusion
Trial: 26799345
Drug: Cyclosporine (CS)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CS) combined with topical agents
Trial: 26799345
Drug: Cyclosporine (CS)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CS) monotherapy
Trial: 24764674
Drug: Esomeprazole therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole therapy (20 mg esomeprazole, 400 mg clarithromycin, 750 mg amoxicillin for the first 7 days, all drugs given twice daily)
Trial: 24764674
Drug: Lansoprazole therapy
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole therapy (30 mg lansoprazole, 400 mg clarithromycin, 750 mg amoxicillin for the first 7 days, all drugs given twice daily)
Trial: 24764674
Drug: Esomeprazole therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole therapy
Trial: 24764674
Drug: Lansoprazole therapy
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole therapy
Trial: 22435741
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan (various dose sizes) without MAOI‐A
Trial: 22435741
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan (various dose sizes) with MAOI‐A
Trial: 22435741
Drug: Oral almotriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral almotriptan
Trial: 16415708
Drug: Topiramate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (25 to 200 mg/d)
Trial: 1801964
Drug: Danazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (200 mg)
Trial: 1801964
Drug: Danazol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (400 mg)
Trial: 6863583
Drug: experimenter-administered time-out
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimenter-administered time-out of fixed duration
Trial: 6863583
Drug: experimenter-administered time-out
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimenter-administered time-out of duration determined by the subject
Trial: 27862923
Drug: 50% reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% reduction in TacER dose with targeted TacER trough level (C0) >3 μg/L (Group A)
Trial: 27862923
Drug: No change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No change in TacER dose (TacER C0 7-12 μg/L) (Group B)
Trial: 25760561
Drug: Low-dose spiral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose spiral computed tomography (LDCT) screening
Trial: 2497135
Drug: GnRH-a treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH-a treatment starting 8-10 days after ovulation (Group 2)
Trial: 6983966
Drug: Carprofen 300
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carprofen 300 mg daily, b.i.d. administration
Trial: 6983966
Drug: Carprofen 300
RxNorm normalized name: Carprofen
DrugBank: Carprofen (DB00821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carprofen 300 mg daily, t.i.d. administration
Trial: 24733007
Drug: Active pharmacotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active pharmacotherapy
Trial: 21726301
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy (manual reading)
Trial: 21726301
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy (semi-automated reading)
Trial: 19841043
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin D supplements
Trial: 14740153
Drug: D‐hormones (alphacalcidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐hormones (alphacalcidol and calcitriol)
Trial: 3594460
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g oxiracetam
Trial: 22816729
Drug: Linagliptin 2.5
RxNorm normalized name: linagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 2.5 mg twice daily
Trial: 19710003
Drug: Ultra-low-dose end-expiratory
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose end-expiratory CT
Trial: 15639696
Drug: DMPA 104
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA 104 mg/0.65 mL SC injection